Nutex Health Statistics
Total Valuation
Nutex Health has a market cap or net worth of $1.14 billion. The enterprise value is $1.33 billion.
| Market Cap | 1.14B |
| Enterprise Value | 1.33B |
Important Dates
The last earnings date was Wednesday, November 19, 2025, after market close.
| Earnings Date | Nov 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutex Health has 7.07 million shares outstanding. The number of shares has increased by 40.46% in one year.
| Current Share Class | 7.07M |
| Shares Outstanding | 7.07M |
| Shares Change (YoY) | +40.46% |
| Shares Change (QoQ) | +19.73% |
| Owned by Insiders (%) | 27.87% |
| Owned by Institutions (%) | 26.68% |
| Float | 4.54M |
Valuation Ratios
The trailing PE ratio is 8.95 and the forward PE ratio is 9.20.
| PE Ratio | 8.95 |
| Forward PE | 9.20 |
| PS Ratio | 0.98 |
| Forward PS | 1.18 |
| PB Ratio | 3.50 |
| P/TBV Ratio | 4.04 |
| P/FCF Ratio | 6.53 |
| P/OCF Ratio | 6.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.51, with an EV/FCF ratio of 7.64.
| EV / Earnings | 11.04 |
| EV / Sales | 1.36 |
| EV / EBITDA | 3.51 |
| EV / EBIT | 3.71 |
| EV / FCF | 7.64 |
Financial Position
The company has a current ratio of 3.20, with a Debt / Equity ratio of 0.82.
| Current Ratio | 3.20 |
| Quick Ratio | 3.09 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | 0.94 |
| Debt / FCF | 2.06 |
| Interest Coverage | 16.10 |
Financial Efficiency
Return on equity (ROE) is 101.68% and return on invested capital (ROIC) is 38.04%.
| Return on Equity (ROE) | 101.68% |
| Return on Assets (ROA) | 31.98% |
| Return on Invested Capital (ROIC) | 38.04% |
| Return on Capital Employed (ROCE) | 46.08% |
| Revenue Per Employee | $1.23M |
| Profits Per Employee | $150,710 |
| Employee Count | 800 |
| Asset Turnover | 1.40 |
| Inventory Turnover | 155.36 |
Taxes
In the past 12 months, Nutex Health has paid $64.29 million in taxes.
| Income Tax | 64.29M |
| Effective Tax Rate | 19.63% |
Stock Price Statistics
The stock price has increased by +311.32% in the last 52 weeks. The beta is 2.01, so Nutex Health's price volatility has been higher than the market average.
| Beta (5Y) | 2.01 |
| 52-Week Price Change | +311.32% |
| 50-Day Moving Average | 116.64 |
| 200-Day Moving Average | 106.07 |
| Relative Strength Index (RSI) | 67.53 |
| Average Volume (20 Days) | 199,231 |
Short Selling Information
The latest short interest is 806,369, so 11.40% of the outstanding shares have been sold short.
| Short Interest | 806,369 |
| Short Previous Month | 838,519 |
| Short % of Shares Out | 11.40% |
| Short % of Float | 17.74% |
| Short Ratio (days to cover) | 7.82 |
Income Statement
In the last 12 months, Nutex Health had revenue of $981.20 million and earned $120.57 million in profits. Earnings per share was $17.98.
| Revenue | 981.20M |
| Gross Profit | 560.39M |
| Operating Income | 358.98M |
| Pretax Income | 327.54M |
| Net Income | 120.57M |
| EBITDA | 379.61M |
| EBIT | 358.98M |
| Earnings Per Share (EPS) | $17.98 |
Balance Sheet
The company has $166.05 million in cash and $358.60 million in debt, giving a net cash position of -$192.55 million or -$27.23 per share.
| Cash & Cash Equivalents | 166.05M |
| Total Debt | 358.60M |
| Net Cash | -192.55M |
| Net Cash Per Share | -$27.23 |
| Equity (Book Value) | 438.03M |
| Book Value Per Share | 45.93 |
| Working Capital | 407.20M |
Cash Flow
In the last 12 months, operating cash flow was $177.79 million and capital expenditures -$3.51 million, giving a free cash flow of $174.28 million.
| Operating Cash Flow | 177.79M |
| Capital Expenditures | -3.51M |
| Free Cash Flow | 174.28M |
| FCF Per Share | $24.64 |
Margins
Gross margin is 57.11%, with operating and profit margins of 36.59% and 12.29%.
| Gross Margin | 57.11% |
| Operating Margin | 36.59% |
| Pretax Margin | 33.38% |
| Profit Margin | 12.29% |
| EBITDA Margin | 38.69% |
| EBIT Margin | 36.59% |
| FCF Margin | 17.76% |
Dividends & Yields
Nutex Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.46% |
| Shareholder Yield | -40.46% |
| Earnings Yield | 10.59% |
| FCF Yield | 15.31% |
Analyst Forecast
The average price target for Nutex Health is $252.50, which is 56.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $252.50 |
| Price Target Difference | 56.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 3, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Nutex Health has an Altman Z-Score of 2.8 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.8 |
| Piotroski F-Score | 8 |